SANSURE BIOTECH INC. Funds and ETFs Sansure Biotech Inc.
Equities
688289
CNE1000043J1
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.58 CNY | +0.11% |
|
-4.04% | -10.08% |
| 06-12 | Sansure Biotech's Tuberculosis Diagnostic Kit Gets EU Certification | MT |
| 04-26 | Sansure Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
ETFs positioned on Sansure Biotech Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.04% | 1 M€ | -18.20% | - | |
| 0.12% | 12 M€ | -16.71% | - |
Sansure Biotech Inc is a company mainly engaged in research and development, production and sales of diagnostic reagents and instruments. The Company's diagnostic reagent products are comprised of viral hepatitis series, reproductive tract infection and genetic series, pediatric infection series and nucleic acid blood screening series. The instrument products include automatic nucleic acid detection reaction system construction series and fluorescent polymerase chain reaction (PCR) monitoring and analysis software. The Company also provides related inspection services, including medical inspection and scientific research services which are provided for medical institutions.
Calendar
26/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
17.58
CNY
Average target price
25
CNY
Spread / Average Target
+42.21%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.08% | 1.39B | |
| -11.93% | 11.24B | |
| -13.76% | 7.29B | |
| +29.50% | 5.57B | |
| -19.19% | 3.68B | |
| +7.62% | 2.58B | |
| -65.24% | 2.33B | |
| -10.89% | 2.23B | |
| +27.80% | 2.21B | |
| -19.12% | 1.57B |
- Stock Market
- Equities
- 688289 Stock
- Funds and ETFs Sansure Biotech Inc.
